Counterpoint: Postprandial Glucose Levels Are Not a Clinically Important Treatment Target
Open Access
- 1 August 2010
- journal article
- editorial
- Published by American Diabetes Association in Diabetes Care
- Vol. 33 (8) , 1908-1910
Abstract
No abstract availableThis publication has 50 references indexed in Scilit:
- Effect of Valsartan on the Incidence of Diabetes and Cardiovascular EventsNew England Journal of Medicine, 2010
- Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trialDiabetes Care, 2009
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesNew England Journal of Medicine, 2009
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic PatientsDiabetes, 2008
- (How) Can We Prevent Type 2 Diabetes?Diabetes, 2007
- Patients with type 2 diabetes have normal mitochondrial function in skeletal muscleDiabetologia, 2007
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialThe Lancet, 2006
- Postprandial Glucose Regulation and Diabetic ComplicationsArchives of internal medicine (1960), 2004